Search results
Results From The WOW.Com Content Network
This page was last edited on 18 September 2020, at 16:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Biotech Consortium India Limited (BCIL), New Delhi was incorporated as public limited company in 1990 under The Companies Act, 1956. [1] The consortium is promoted by the Department of Biotechnology , Government of India and financed by the All India Financial Institutions and some corporate sectors. [ 2 ]
In 2004–5, the Indian biotech industry saw its revenues grow 37% to $1.1 billion. The Indian biotech market is dominated by biopharmaceuticals; 76% of 2004–5 revenues came from biopharmaceuticals, which saw 30% growth last year. Of the revenues from biopharmaceuticals, vaccines led the way, comprising 47% of sales.
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India.It was founded by Kiran Mazumdar-Shaw in 1978. [4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [5] including the United States and Europe. [4]
The Regional Centre for Biotechnology (RCB) [1] is an autonomous institution of education, training and research established under the auspices of United Nations Educational, Scientific and Cultural Organization (UNESCO) and Department of Biotechnology (DBT, India).
The main IGIB campus is located at Mall Road, New Delhi near Delhi University North Campus. IGIB's alliance with the Biotech/Pharmaceuticals has led to its growth and setting up of two extension centers - one at South Delhi (IGIB Annex at TCGA, Okhla) and the other at Western Delhi at Naraina.
Panacea Biotec has a focused presence in nephrology therapy in the highly specialized organ transplantation and dialysis management segments. It offers a range of pre-transplant and post-transplant therapies that include drugs such as lanthanum carbonate, sevelamer, and valganciclovir in conventional and novel drug delivery systems.
The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed.They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". [8]